Back to Search Start Over

Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer

Authors :
Rebbeck, T.R.
Mitra, N.
Wan, F.
Sinilnikova, O.M.
Healey, S.
McGuffog, L.
Mazoyer, S.
Chenevix-Trench, G.
Easton, D.F.
Antoniou, A.C.
Nathanson, K.L.
Laitman, Y.
Kushnir, A.
Paluch-Shimon, S.
Berger, R.
Zidan, J.
Friedman, E.
Ehrencrona, H.
Stenmark-Askmalm, M.
Einbeigi, Z.
Loman, N.
Harbst, K.
Rantala, J.
Melin, B.
Huo, D.
Olopade, O.I.
Seldon, J.
Ganz, P.A.
Nussbaum, R.L.
Chan, S.B.
Odunsi, K.
Gayther, S.A.
Domchek, S.M.
Arun, B.K.
Lu, K.H.
Mitchell, G.
Karlan, B.Y.
Walsh, C.
Lester, J.
Godwin, A.K.
Pathak, H.
Ross, E.
Daly, M.B.
Whittemore, A.S.
John, E.M.
Miron, A.
Terry, M.B.
Chung, W.K.
Goldgar, D.E.
Buys, S.S.
Janavicius, R.
Tihomirova, L.
Tung, N.
Dorfling, C.M.
Rensburg, E.J. van
Steele, L.
Neuhausen, S.L.
Ding, Y.C.
Ejlertsen, B.
Gerdes, A.M.
Hansen, T.
Ramon Y Cajal, T.
Osorio, A.
Benitez, J.
Godino, J.
Tejada, M.I.
Duran, M.
Weitzel, J.N.
Bobolis, K.A.
Sand, S.R.
Fontaine, A.
Savarese, A.
Pasini, B.
Peissel, B.
Bonanni, B.
Zaffaroni, D.
Vignolo-Lutati, F.
Scuvera, G.
Giannini, G.
Bernard, L.
Genuardi, M.
Radice, P.
Dolcetti, R.
Manoukian, S.
Pensotti, V.
Gismondi, V.
Yannoukakos, D.
Fostira, F.
Garber, J.
Torres, D.
Rashid, M.U.
Hamann, U.
Peock, S.
Frost, D.
Platte, R.
Evans, D.G.
Eeles, R.
Davidson, R.
Eccles, D.
Cole, T.
Kets, M.
Mensenkamp, A.R.
et al.
Rebbeck, T.R.
Mitra, N.
Wan, F.
Sinilnikova, O.M.
Healey, S.
McGuffog, L.
Mazoyer, S.
Chenevix-Trench, G.
Easton, D.F.
Antoniou, A.C.
Nathanson, K.L.
Laitman, Y.
Kushnir, A.
Paluch-Shimon, S.
Berger, R.
Zidan, J.
Friedman, E.
Ehrencrona, H.
Stenmark-Askmalm, M.
Einbeigi, Z.
Loman, N.
Harbst, K.
Rantala, J.
Melin, B.
Huo, D.
Olopade, O.I.
Seldon, J.
Ganz, P.A.
Nussbaum, R.L.
Chan, S.B.
Odunsi, K.
Gayther, S.A.
Domchek, S.M.
Arun, B.K.
Lu, K.H.
Mitchell, G.
Karlan, B.Y.
Walsh, C.
Lester, J.
Godwin, A.K.
Pathak, H.
Ross, E.
Daly, M.B.
Whittemore, A.S.
John, E.M.
Miron, A.
Terry, M.B.
Chung, W.K.
Goldgar, D.E.
Buys, S.S.
Janavicius, R.
Tihomirova, L.
Tung, N.
Dorfling, C.M.
Rensburg, E.J. van
Steele, L.
Neuhausen, S.L.
Ding, Y.C.
Ejlertsen, B.
Gerdes, A.M.
Hansen, T.
Ramon Y Cajal, T.
Osorio, A.
Benitez, J.
Godino, J.
Tejada, M.I.
Duran, M.
Weitzel, J.N.
Bobolis, K.A.
Sand, S.R.
Fontaine, A.
Savarese, A.
Pasini, B.
Peissel, B.
Bonanni, B.
Zaffaroni, D.
Vignolo-Lutati, F.
Scuvera, G.
Giannini, G.
Bernard, L.
Genuardi, M.
Radice, P.
Dolcetti, R.
Manoukian, S.
Pensotti, V.
Gismondi, V.
Yannoukakos, D.
Fostira, F.
Garber, J.
Torres, D.
Rashid, M.U.
Hamann, U.
Peock, S.
Frost, D.
Platte, R.
Evans, D.G.
Eeles, R.
Davidson, R.
Eccles, D.
Cole, T.
Kets, M.
Mensenkamp, A.R.
et al.
Source :
Jama : Journal of the American Medical Association; 1347; 1361; 0098-7484; 13; 313; ~Jama : Journal of the American Medical Association~1347~1361~~~0098-7484~13~313~~
Publication Year :
2015

Abstract

Item does not contain fulltext<br />IMPORTANCE: Limited information about the relationship between specific mutations in BRCA1 or BRCA2 (BRCA1/2) and cancer risk exists. OBJECTIVE: To identify mutation-specific cancer risks for carriers of BRCA1/2. DESIGN, SETTING, AND PARTICIPANTS: Observational study of women who were ascertained between 1937 and 2011 (median, 1999) and found to carry disease-associated BRCA1 or BRCA2 mutations. The international sample comprised 19,581 carriers of BRCA1 mutations and 11,900 carriers of BRCA2 mutations from 55 centers in 33 countries on 6 continents. We estimated hazard ratios for breast and ovarian cancer based on mutation type, function, and nucleotide position. We also estimated RHR, the ratio of breast vs ovarian cancer hazard ratios. A value of RHR greater than 1 indicated elevated breast cancer risk; a value of RHR less than 1 indicated elevated ovarian cancer risk. EXPOSURES: Mutations of BRCA1 or BRCA2. MAIN OUTCOMES AND MEASURES: Breast and ovarian cancer risks. RESULTS: Among BRCA1 mutation carriers, 9052 women (46%) were diagnosed with breast cancer, 2317 (12%) with ovarian cancer, 1041 (5%) with breast and ovarian cancer, and 7171 (37%) without cancer. Among BRCA2 mutation carriers, 6180 women (52%) were diagnosed with breast cancer, 682 (6%) with ovarian cancer, 272 (2%) with breast and ovarian cancer, and 4766 (40%) without cancer. In BRCA1, we identified 3 breast cancer cluster regions (BCCRs) located at c.179 to c.505 (BCCR1; RHR = 1.46; 95% CI, 1.22-1.74; P = 2 x 10(-6)), c.4328 to c.4945 (BCCR2; RHR = 1.34; 95% CI, 1.01-1.78; P = .04), and c. 5261 to c.5563 (BCCR2', RHR = 1.38; 95% CI, 1.22-1.55; P = 6 x 10(-9)). We also identified an ovarian cancer cluster region (OCCR) from c.1380 to c.4062 (approximately exon 11) with RHR = 0.62 (95% CI, 0.56-0.70; P = 9 x 10(-17)). In BRCA2, we observed multiple BCCRs spanning c.1 to c.596 (BCCR1; RHR = 1.71; 95% CI, 1.06-2.78; P = .03), c.772 to c.1806 (BCCR1'; RHR = 1.63; 95% CI, 1.10-2.40; P = .01), and c.73

Details

Database :
OAIster
Journal :
Jama : Journal of the American Medical Association; 1347; 1361; 0098-7484; 13; 313; ~Jama : Journal of the American Medical Association~1347~1361~~~0098-7484~13~313~~
Publication Type :
Electronic Resource
Accession number :
edsoai.on1286029612
Document Type :
Electronic Resource